Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study.

Siliang ZhangJiaoxia HeBin TangQin ZhouYudong HuYuan YuJianwei ChenYi LiuChunmeng LiHong RenXiaohui Liao

Published in: Journal of clinical medicine (2023)

The recombinant and inactivated SARS-CoV-2 vaccine was well-tolerated and showed a good response in the CKD cohort. Our study also revealed differences in MBC subtypes after SARS-CoV-2 vaccination between CKD patients and healthy controls.

Keyphrases

sars cov
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
respiratory syndrome coronavirus
prognostic factors
immune response
patient reported outcomes